Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder in Children: Incidence, Prevalence, and Treatment Patterns in The Netherlands

Clinical Therapeutics

Volumn 33, Issue 2, 2011, Pages 188-203

  Hodgkins, Paul ^a   Sasané, Rahul ^a   Meijer, Willemijn M ^b  

^a SHIRE   (United States)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

ADHD; Incidence; Prevalence; The Netherlands; Treatment pattern

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; MELATONIN; METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NETHERLANDS; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PEDIATRICS; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; SCHOOL CHILD;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HUMANS; INCIDENCE; MEDICAL RECORDS; METHYLPHENIDATE; NETHERLANDS; PATIENT COMPLIANCE; PREVALENCE; PROPYLAMINES; RETROSPECTIVE STUDIES;

EID: 79954554520     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.03.001     Document Type: Article

References (54)

1. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. Clinical guidelines CG72 National Institute for Health and Clinical Excellence, Accessed February 28, 2011. http://guidance.nice.org.uk/CG72.
2. Makris N., Biederman J., Monuteaux M.C., Seidman L.J. Towards conceptualizing a neural systems-based anatomy of attention-deficit/hyperactivity disorder. Dev Neurosci 2009, 31:36-49.
3. Schubiner H., Katragadda S. Overview of epidemiology, clinical features, genetics, neurobiology, and prognosis of adolescent attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev 2008, 19:209-215. vii.
4. Boulougouris V., Tsaltas E. Serotonergic and dopaminergic modulation of attentional processes. Prog Brain Res 2008, 172:517-542.
5. Kelleher K.J., McInerny T.K., Gardner W.P., et al. Increasing identification of psychosocial problems: 1979-1996. Pediatrics 2000, 105:1313-1321.
6. Mandell D.S., Thompson W.W., Weintraub E.S., et al. Trends in diagnosis rates for autism and ADHD at hospital discharge in the context of other psychiatric diagnoses. Psychiatr Serv 2005, 56:56-62.
7. Polanczyk G., de Lima M.S., Horta B.L., et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948.
8. Schirm E., Tobi H., Zito J.M., de Jong-van den Berg L.T. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001, 108:E25.
9. Faber A., de Jong-van den Berg L.T., van den Berg P.B., Tobi H. Psychotropic co-medication among stimulant-treated children in The Netherlands. J Child Adolesc Psychopharmacol 2005, 15:38-43.
10. Froehlich T.E., Lanphear B.P., Epstein J.N., et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007, 161:857-864.
11. Cuffe S.P., Moore C.G., McKeown R.E. Prevalence and correlates of ADHD symptoms in the national health interview survey. J Atten Disord 2005, 9:392-401.
12. Bussing R., Zima B.T., Gary F.A., Garvan C.W. Barriers to detection, help-seeking, and service use for children with ADHD symptoms. J Behav Health Serv Res 2003, 30:176-189.
13. Pastor P.N., Reuben C.A. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 2008, 10(237):1-14.
14. Coghill D., Soutullo C., d'Aubuisson C., et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health 2008, 2:31.
15. Noe L., Hankin C. Health outcomes of childhood attention-deficit/ hyperactivity disorder (ADHD): Health care use and work status of caregivers. Value Health 2001, 4:142-143.
16. De Ridder A., De Graeve D. Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Investig 2006, 26:75-90.
17. Hakkaart-van Roijen L., Zwirs B.W., Bouwmans C., et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007, 16:316-326.
18. Pelham W.E., Foster E.M., Robb J.A. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambul Pediatr 2007, 7(Suppl 1):121-131.
19. Connor D.F., Steeber J., McBurnett K. A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr 2010, 31:427-440.
20. Gau S.S., Ni H.C., Shang C.Y., et al. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust N Z J Psychiatry 2010, 44:135-143.
21. Ter-Stepanian M., Grizenko N., Zappitelli M., Joober R. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Can J Psychiatry 2010, 55:305-312.
22. Spencer T.J., Biederman J., Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007, 32:631-642.
23. Banaschewski T., Coghill D., Santosh P., et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006, 15:476-495.
24. van den Ban E., Souverein P., Swaab H., et al. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. J Child Adolesc Psychopharmacol 2010, 20:55-61.
25. Faber A., Kalverdijk L.J., de Jong-van den Berg L.T., et al. Parents report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care. J Child Adolesc Psychopharmacol 2006, 16:432-440.
26. Meijer W.M., Faber A., van den Ban E., Tobi H. Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci 2009, 31:509-516.
27. Diagnosis and treatment of ADHD Health Council of the Netherlands, Accessed February 28, 2011. http://www.gezondheidsraad.nl/en/publications/diagnosis-and-treatment-adhd.
28. Herings R.M., Bakker A., Stricker B.H., Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992, 46:136-140.
29. Herings R.M. The PHARMO System. CNS Spectr 2007, 9(Suppl 16):14-17.
30. van Herk-Sukel M.P., van de Poll-Franse L.V., Lemmens V.E., et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010, 46:395-404.
31. DDD: Definition and general considerations World Health Organization, Accessed February 28, 2011. http://www.whocc.no/ddd.
32. Herings R.M., de Boer A., Stricker B.H., et al. A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharm World Sci 1995, 17:17-19.
33. Catalan V.S., LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000, 3:417-426.
34. Karve S., Cleves M.A., Helm M., et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009, 25:2303-2310.
35. Perwien A., Hall J., Swensen A., Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004, 10:122-129.
36. Huss M., Hölling H., Kurth B.M., Schlack R. How often are German children and adolescents diagnosed with ADHD?. Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry 2008, 17(Suppl 1):52-58.
37. Smalley S.L., McGough J.J., Moilanen I.K., et al. Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish population. J Am Acad Child Adolesc Psychiatry 2007, 46:1575-1583.
38. Derks E.M., Hudziak J.J., Boomsma D.I. Why more boys than girls with ADHD receive treatment: a study of Dutch twins. Twin Res Hum Genet 2007, 10:765-770.
39. Novik T.S., Hervas A., Ralston S.J., et al. Influence of gender on attention-deficit/hyperactivity disorder in Europe-ADORE. Eur Child Adolesc Psychiatry 2006, 15(Suppl 1):I15-I24. ADORE Study Group.
40. Bitter I., Simon V., Bálint S., et al. How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults?. An epidemiological study in a Hungarian community sample. Eur Arch Psychiatry Clin Neurosci 2010, 260:287-296.
41. Robison R.J., Reimherr F.W., Marchant B.K., et al. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 2008, 69:213-221.
42. Zuvekas S.H., Vitiello B., Norquist G.S. Recent trends in stimulant medication use among U.S. children [published correction appears in Am J Psychiatry. 2006;163:942]. Am J Psychiatry 2006, 163:579-585.
43. Winterstein A.G., Gerhard T., Shuster J., et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008, 42:24-31.
44. Preen D.B., Calver J., Sanfilippo F.M., et al. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed. Aust N Z J Public Health 2007, 31:120-126.
45. Hoebert M., van der Heijden K.B., van Geijlswijk I.M., Smits M.G. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res 2009, 47:1-7.
46. Van der Heijden K.B., Smits M.G., Van Someren E.J., et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry 2007, 46:233-241.
47. Weiss M.D., Wasdell M.B., Bomben M.M., et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry 2006, 45:512-519.
48. Kemner J.E., Lage M.J. Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm 2006, 63:317-322.
49. Lage M., Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 2004, 14:575-581.
50. Sanchez R.J., Crismon M.L., Barner J.C., et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005, 25:909-917.
51. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guidelines CG76 National Institute for Health and Clinical Excellence, Accessed February 28, 2011. http://guidance.nice.org.uk/CG76.
52. Hsia Y., Neubert A.C., Rani F., et al. An increase in the prevalence of type 1 and 2 diabetes in children and adolescents: results from prescription data from a UK general practice database. Br J Clin Pharmacol 2009, 67:242-249.
53. Wong I.C., Asherson P., Bilbow A., et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)-a pharmacoepidemiological and qualitative study. Health Technol Assess 2009, 13:1-120. iii-iv, ix-xi.
54. Faber A., Kalverdijk L.J., de Jong-van den Berg L.T., et al. Parents report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care. J Child Adolesc Psychopharmacol 2006, 16:432-440.